Chemical Features of Bisphosphonates and Histopathological Outcomes in Rat Jaw Treated with Zoledronic Acid Combined with Dexamethasone

被引：0

作者：

Stan, Ioana Aurita Albu ^{[1
]}

Petrovan, Cecilia ^{[2
]}

Cerghizan, Diana ^{[1
]}

Albu, Daniel Emil ^{[3
]}

Craciun, Adriana Elena ^{[1
]}

Copotoiu, Constantin ^{[4
]}

机构：

[1] Univ Med & Pharm, Dept Fixed Prosthodont, 38 Gheorghe Marinescu Str, Targu Mures 540139, Romania

[2] Univ Med & Pharm, Dept Oral & Maxillofacial Surg, 38 Gheorghe Marinescu Str, Targu Mures 540139, Romania

[3] County Emergency Clin Hosp, Dept Orthoped Surg & Traumatol 1, 50 Gheorghe Marinescu Str, Targu Mures 540136, Romania

[4] Cty Emergency Clin Hosp, Dept Surg Clin 1, 50 Gheorghe Marinescu Str, Targu Mures 540136, Romania

来源：

REVISTA DE CHIMIE | 2018年 / 69卷 / 07期

关键词：

bisphosphonates; dexamethasone; osteonecrosis; jaw; zoledronic acid; SURGEONS POSITION PAPER; AMERICAN ASSOCIATION; BONE-RESORPTION; CANCER-PATIENTS; RISK-FACTORS; OSTEONECROSIS; MECHANISMS; EXTRACTION; BINDING; UPDATE;

D O I：

暂无

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

Bisphosphonate related osteonecrosis of the jaws (BRONJ) is a pathological entity described for the first time in 2003; three criteria are mandatory: no radiotion therapy, exposed bone in oral cavities for at least eight weeks with no signs of healing, bisphosphonate therapy in present or in the past, in patients with bisphosphonate therapy in present or in the past. Bisphosphonates (BPs) are stable analogues of natural inorganic pyrophosphate, which inhibit bone resorption. In literature, most patients diagnosed with BRONJ were suffering from multiple myeloma and they had a treatment with nitrogen containing BPs and steroids such as dexamethasone intravenously. With this study we have aimed to achieve a rat model of BRONJ and to evaluate histopathological findings how concurrent use of BPs and steroids can affect emergence of BRONJ in this study.

引用

页码：1802 / 1807

页数：6

共 41 条

[1]

Antohe ME, 2017, ROM J ORAL REHABIL, V9, P94

[2]

Benedict JJ., 1982, S CEMO CTR DETUDE MA, P1

[3] Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates:: Biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs [J].